On 20 Oct 2026, CSPC PHARMA (01093.HK) launched a Phase I trial in China of SYH2083 eye drops, a dual LFA-1/RASP inhibitor for dry eye disease.
On 20 October 2026, DEEPEXI TECH (01384.HK) said DeepWorks opened self-service registration for all users from 15 October, with services charged by Token usage
On 20 Oct 2026, BIOSTAR PHARM-B (02563.HK) dosed the first patient in a Phase III trial of utidelone capsules in HER2-negative advanced breast cancer.
On 20 Oct 2026, BAO PHARMA-B (02659.HK) said NMPA approved the IND for BJ045 injection, a subcutaneous anti-CD20 antibody for use with IgG-degrading enzymes.
On October 20, 2026, the HSTECH fell 1.52% to a fresh low and the HSI lost 1.32%. UBTECH ROBOTICS led AI concept stocks with a 6.04% gain; Z.AI dropped 6.41%.
ASMPT (00522.HK) fell 3.62% to HKD 133.000; its CFO joined the board on 19 October and advanced packaging is set to top 50% of the OSAT market in 2026.
XIAOMI-W (01810.HK) rose 1.50% to HKD 27.060; China's H1 humanoid robot output topped 40,000 units and 18 measures were issued to boost embodied AI in commerce.
On 20 October 2026, VIRTUAL MIND (01520.HK) said DolphinOne 2.0, its AI creation and agent platform, is now available globally on the Apple App Store.
On October 20, 2026, BIDU-W (09888.HK) traded weaker intraday. As of 09:42, the stock was quoted at HK$77.85, down 2.01%.
On 20 October 2026, OCUMENSION-B (01477.HK) said its OT-101 Phase III trial met the China primary endpoint at month 36, with myopia progression below placebo.
On 20 October 2026, INSILICO (03696.HK) said its AI drug discovery collaboration with Servier reached an early milestone, triggering an undisclosed payment.
On 20 October 2026, ASCLETIS-B (01672.HK) reported positive preclinical data for weekly oral peptide pipeline, with ASC36o showing a 7-day half-life in monkeys.
On 19 Oct 2026, LEADS BIOLABS-B (09887.HK) said six Weilixin and LBL-034 abstracts were published for ESMO 2026, 3 selected for preferred oral presentations.
On 19 Oct 2026, MABWELL-B (02493.HK) said Phase II data for 9MW2821 in TNBC will be presented at ESMO 2026: ORR 30.0% and DCR 80.0% in 60 evaluable patients.
On 19 Oct 2026, SHANDONG XINHUA (00719.HK) said nimodipine tablets passed China's generic-drug consistency evaluation, with 2025 hospital sales of ~RMB 130mn.
On October 16, 2026, the HSTECH rose 1.16% and the HSI gained 0.52%. MONTAGETECH led AI concept stocks with a 4.55% gain, while HUA HONG GRACE fell 2.09%.
